LONDON, Nov. 15, 2017 /PRNewswire/ --
General Report Contents- Market Analyses include: Unit Sales, ASPs, Market Value & Growth TrendsDownload the full report: https://www.reportbuyer.com/product/4785425- Market Drivers & Limiters for each chapter segment- Competitive Analysis for each chapter segment- Section on recent mergers & acquisitionsThe transcervical implant market in Europe currently consists of Bayer AG as the sole competitor offering the Essure® procedure. Essure® was first developed by the company Conceptus in 2001 and was certified for sale throughout Europe, with the first sale occurring in October 2002. In the United States, Essure® was subsequently approved by the FDA on November 4th, 2002. In April 2013, Bayer AG acquired Conceptus to offer Essure® as part of their contraceptive portfolio. The United Kingdom was the last country to approve the Essure® procedure in Europe, with NICE granting approval in 2009. Since the Essure® procedure entered the market in 2002, other notable competitors have been the Ovabloc System and the Adiana procedure. Both of these procedures have since been discontinued. AbstractFemale sterilization is a permanent form of birth control, requiring invasive surgery to reverse. Female sterilization prevents ova from coming down the fallopian tubes and blocks fertilization by sperm. There are different procedures to perform female sterilization, including tubal ligation, mechanical blockage with a clip or band, bipolar electrocoagulation or transcervical implants. In this report, only the transcervical implant market is covered.Download the full report: https://www.reportbuyer.com/product/4785425 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
Advertisement
General Report Contents- Market Analyses include: Unit Sales, ASPs, Market Value & Growth TrendsDownload the full report: https://www.reportbuyer.com/product/4785425- Market Drivers & Limiters for each chapter segment- Competitive Analysis for each chapter segment- Section on recent mergers & acquisitionsThe transcervical implant market in Europe currently consists of Bayer AG as the sole competitor offering the Essure® procedure. Essure® was first developed by the company Conceptus in 2001 and was certified for sale throughout Europe, with the first sale occurring in October 2002. In the United States, Essure® was subsequently approved by the FDA on November 4th, 2002. In April 2013, Bayer AG acquired Conceptus to offer Essure® as part of their contraceptive portfolio. The United Kingdom was the last country to approve the Essure® procedure in Europe, with NICE granting approval in 2009. Since the Essure® procedure entered the market in 2002, other notable competitors have been the Ovabloc System and the Adiana procedure. Both of these procedures have since been discontinued. AbstractFemale sterilization is a permanent form of birth control, requiring invasive surgery to reverse. Female sterilization prevents ova from coming down the fallopian tubes and blocks fertilization by sperm. There are different procedures to perform female sterilization, including tubal ligation, mechanical blockage with a clip or band, bipolar electrocoagulation or transcervical implants. In this report, only the transcervical implant market is covered.Download the full report: https://www.reportbuyer.com/product/4785425 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/europe-market-report-for-transcervical-female-sterilization-2017---medcore-300557289.html
SOURCE ReportBuyer
